The United States’ (US) engagement of public health resources to meet the current SARS-CoV-2 (COVID-19) crisis has revealed vulnerabilities in testing and treatment components of biosecurity. Facing a severe shortage of available testing kits, the US Centers for Disease Control (CDC) attempted to develop its own test for COVID-19, rather than following World Health Organization (WHO) recommendations for testing methods. The lack of tests has made it difficult to track exactly how many people within each state, as well as the US at-large have been affected, which has implications both for the extent of public health response, and considerations for approaches to stabilize and sustain the national economy.
Format: |
|
Topics: | |
Website: | Visit Publisher Website |
Publisher: | Strategic Multilayer Assessment Office |
Published: | April 22, 2020 |
License: | Public Domain |